Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
4.961
Journals
Vaccines
Special Issues
Research and Development on Therapeutic Agents and Vaccines for COVID-19
share announcement

Special Issue "Research and Development on Therapeutic Agents and Vaccines for COVID-19"

A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Therapeutic Vaccines and Antibody Therapeutics".

Deadline for manuscript submissions: 30 November 2023 | Viewed by 1279

Special Issue Editors

Dr. Ahmed Kamal

E-Mail Website
Guest Editor
Birla Institute of Technology & Science, Pilani Hyderabad Campus, Dist.- Medchal, Telangana 500 078, India
Interests: emerging infectious diseases; design and synthesis of gene-targeting compounds; public health
Dr. Swapna Ponnampalli

E-Mail Website
Guest Editor
CVR College of Engineering, Mangalpalle, Hyderabad, India
Interests: emerging infectious diseases; public health; pandemic response

Special Issue Information

Dear Colleagues,

The impact of the COVID-19 pandemic on humankind is persistent, despite the availability of a number of vaccines and some approved therapeutic agents. The continuous evolution of SARS-CoV-2 demands a broadly neutralizing therapy against current and emergent variants that may be helpful for both prevention and treatment. SARS-CoV-2 may not be the last human coronavirus to emerge from animals. To understand the virus replication and mutation mechanism, close monitoring of their populations in the early stages and the investigation of new druggable targets are promising strategies.

We invite contributions from the international community of researchers for this Special Issue on the ongoing progress in COVID-19 research. The goal of this Special Issue is to communicate the recent advances in the domain to the scientific community which may help to focus on the new strategies for containing the COVID-19 virus. In this Special Issue, original research articles and reviews are welcome. Research areas may include (but are not limited to) the discovery of vaccines or drugs/drug targets and the ongoing research and development of vaccines and therapeutic strategies to fight against SARS-CoV-2.

Dr. Ahmed Kamal
Dr. Swapna Ponnampalli
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • coronavirus
  • SARS-CoV-2
  • new variants of SARS-CoV-2
  • COVID-19 vaccines
  • vaccine efficacy
  • COVID-19 therapeutics
  • COVID-19 therapeutic targets

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

get_app
Article
Salivary Antibody Responses to Two COVID-19 Vaccines following Different Vaccination Regimens
by
Hassan Alkharaan
,
Hatem Al-Qarni
,
Muath A. Aldosari
,
Mohammed Alsaloum
,
Ghada Aldakheel
,
Mohammed W. Alenazi
and
Naif Khalaf Alharbi
Vaccines 2023, 11(4), 744; https://doi.org/10.3390/vaccines11040744 - 28 Mar 2023
Viewed by 809
Abstract
Background: To date, little is known about the salivary mucosal immune response following different COVID-19 vaccine types or after a booster (3rd) dose of the BNT162b2 (BNT) vaccine. Methods: A total of 301 saliva samples were collected from vaccinated individuals and arranged into [...] Read more.
Background: To date, little is known about the salivary mucosal immune response following different COVID-19 vaccine types or after a booster (3rd) dose of the BNT162b2 (BNT) vaccine. Methods: A total of 301 saliva samples were collected from vaccinated individuals and arranged into two cohorts: cohort 1 (n = 145), samples from individuals who had received two doses against SARS-CoV-2; cohort 2 (n = 156), samples from individuals who had received a booster of BNT vaccine. Cohorts 1 and 2 were sub-stratified into three groups based on the types of first and second doses (homologous BNT/BNT, homologous ChAdOx1/ChAdOx1, or heterologous BNT/ChAdOx1vaccinations). Salivary immunoglobulin G (IgG) response to SARS-CoV-2 spike glycoprotein was measured by ELISA, and clinical demographic data were collected from hospital records or questionnaires. Results: Salivary IgG antibody responses against different vaccines, whether homologous or heterogeneous vaccination regimens, showed similar levels in cohorts 1 and 2. Compiling all groups in cohort 1 and 2 showed significant, albeit weak, negative correlations between salivary IgG levels and time (r = −0.2, p = 0.03; r = −0.27, p = 0.003, respectively). In cohort 2, the durability of salivary IgG after a booster dose of BNT162b2 significantly dropped after 3 months compared to the <1 month and 1–3 months groups. Conclusions: Different COVID-19 vaccine types and regimens elicit similar salivary anti-SARS-CoV-2 IgG with modest waning over time. Boosting with BNT162b2 vaccine did not produce an evident increase in mucosal IgG response whereby COVID-19 recovered subjects show higher salivary IgG than naive, post-vaccination subjects. The ChAdOx1/ChAdOx1 regimen showed better correlation between salivary IgG levels and durability. These findings highlight the importance of developing oral or intra-nasal vaccines to induce stronger mucosal immunity. Full article
(This article belongs to the Special Issue Research and Development on Therapeutic Agents and Vaccines for COVID-19)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop